Test Price
2,800 AED✅ Home Collection Available
AFG3L2 Gene Spinocerebellar Ataxia Type 28, Autosomal Dominant Genetic Test – Dubai, UAE
Executive Summary & Core Metrics
- ✓ Accuracy Guarantee: 99.9% Diagnostic Sensitivity via ISO 9001:2015 accredited processing (Cert: INT/EGQ/2509DA/3139).
- ✓ Premium Logistics: VIP Mobile Phlebotomy & Temperature-Controlled Cold-Chain Home Collection (daily 8 AM–11 PM).
- ✓ Clinical Guidance: Telephonic post-test genetic counselling by DHA-licensed medical geneticist.
- ✓ Insurance: Direct Billing Verification via WhatsApp +971 54 548 8731.
Test Overview & Methodology
The AFG3L2 NGS test detects pathogenic variants in the AFG3L2 gene, which causes autosomal dominant spinocerebellar ataxia type 28 (SCA28), a progressive neurodegenerative disorder. Our next-generation sequencing pipeline provides comprehensive coverage of exonic, splice-site, and copy-number variants, surpassing the limitations of traditional Sanger sequencing.
| Feature | Our Test (AFG3L2 NGS) | Closest Alternative (Sanger Sequencing) |
|---|---|---|
| Precision | High sensitivity for exonic, splice-site, and copy-number variants | Limited to manually targeted exons; misses deep intronic/CNV alterations |
| Method | Next-Generation Sequencing (NGS) – massively parallel, validated clinical pipeline | Capillary electrophoresis (Sanger) – sequential, lower throughput |
| Turnaround Speed | 3–4 weeks | 4–6 weeks (often longer for full gene) |
Physician Insight & Safety Protocols
“As a consultant medical geneticist, I emphasize that a positive AFG3L2 mutation does not predict disease severity or onset age; clinical correlation with a comprehensive neurological examination and family history is essential. A negative result does not exclude other hereditary ataxias, necessitating further genetic counselling. Never adjust your management based solely on this test without consulting your specialist.” – Lina Osama Zaki Quteineh, Consultant Medical Genetics, DHA Registration ID: 9294403.
⚠️ Advisory: Medication and Clinical Precautions
Do not discontinue prescribed medication or alter treatment without consulting your doctor. This test is for diagnostic confirmation and risk assessment; it should not replace clinical judgment.
Exclusion Criteria & Safety Alerts
- Uncontrolled bleeding disorders or active anticoagulant therapy (risk of hematoma).
- Active infection or dermatitis at the venipuncture site.
- Lack of informed consent or inability to comprehend the genetic implications.
- Minors without legal guardian consent.
- 🚨 ER Red Flags: If you experience severe anxiety, depression, or suicidal ideation upon receiving results, immediately call emergency services (998) or our support line at +971 54 548 8731 for post-test counselling.
Patient FAQ & Clinical Guidance
1. What is the clinical significance of detecting an AFG3L2 gene mutation for spinocerebellar ataxia type 28?
This NGS test confirms an autosomal dominant SCA28 diagnosis, enabling targeted management and family risk assessment.
2. How do I prepare for the AFG3L2 genetic test blood draw?
No fasting is required, but you must provide comprehensive clinical and family neurological history.
3. Can this test be done for children or asymptomatic individuals?
Testing minors requires parental consent, and pre-test genetic counselling is mandatory.
UAE Regulatory & Data Privacy Adherence
- All personal genetic data is processed in compliance with Federal Decree-Law No. 45 of 2021 on Personal Data Protection (PDPL) and Federal Law No. 2 of 2019 Concerning the Use of Information and Communication Technology in Health Fields.
- Clinical testing safety and patient consent procedures adhere to Federal Decree-Law No. 4 of 2016 on Medical Liability.
- Laboratory is licensed under DHA Facility License No. 1143 and operates under ISO 9001:2015 quality management (Cert: INT/EGQ/2509DA/3139).
Clinical & Logistical Metadata
| Test Name | AFG3L2 Gene Spinocerebellar Ataxia Type 28, Autosomal Dominant Genetic Test |
| Price (AED) | 2,800 |
| Turnaround Time | 3–4 weeks |
| Sample Type / Matrix | Peripheral whole blood (EDTA tube) |
| Methodology Used | Next-Generation Sequencing (NGS) |
| ICD-10-CM Code | G11.8 (Other hereditary ataxia) |
| LOINC Code | 94475-6 (Genes analyzed for hereditary ataxia) |
| DHA Facility License & Laboratory Address | License No. 1143 – DNA Labs UAE, Premises 105, Floor 1, Building 33, Dubai Healthcare City, Dubai, UAE |
دعم ثنائي اللغة متاح
التحقق من التغطية التأمينية
Check Insurance Coverage Instantly
Stop the guesswork. Send a photo of your Insurance Card and Doctor's Prescription to our DHA-Certified Verification Team on WhatsApp.
توقف عن التخمين. أرسل صورة من بطاقة التأمين ووصفة الطبيب إلى فريق التحقق المعتمد من هيئة الصحة بدبي عبر الواتساب. احصل على تحديث الحالة في دقائق.
Available in Arabic, English, Hindi & Urdu
ISMS 27001:2022
ISO Accredited
HIPAA
All reports reviewed by DHA-Certified physicians